AstraZeneca Pharmaceuticals
Campaign Finance
$659,400 GivenFigures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.
-
Top Recipients
- Employee Color Block
- Individuals
- PAC Color Block
- PAC
-
Republicans vs. Democrats
in dollars -
State vs. Federal
in dollars -
Top PAC Recipients
- Employee Color Block
- Individuals
- PAC Color Block
- PAC
Lobbying
$3,440,000 SpentFigures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying On Behalf of AstraZeneca Pharmaceuticals
-
Names of Lobbyists
-
Firm Hired Amount Williams & Jensen $150,000 Guida Consulting Services $150,000 Mehlman Vogel Castagnetti Inc $150,000 Tarplin, Downs & Young $150,000 East End Group $135,000 Foley Hoag LLP $135,000 Peck, Madigan et al $90,000 Capitol Counsel $90,000 -
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Pharmacy,
- Taxes,
- Trade,
- Consumer Product Safety,
- Fed Budget & Appropriations,
- Government Issues,
- Labor, Antitrust & Workplace
-
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 S.1790 Indian Health Care Improvement Reauthorization and Extension Act of 2009 H.R.4872 Health Care and Education Affordability Reconciliation Act of 2010
Regulations
6 MentionsAll data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "AstraZeneca Pharmaceuticals" in public comments on proposed federal regulations.
-
Mentions in Document Text
